Cominar

Quick links to important sections

Cominar

Method of action: Anti-Inflammatory, Antirheumatic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cominar

What is Cominar? An Overview

Cominar is a prescription medication designed for the long-term management of symptoms associated with osteoarthritis. It contains the single active ingredient Diacerein and works by modifying the disease process within the affected joints.

Property Description
Active Ingredient Diacerein (INN)
Form Hard capsule (Oral)
Pharmacological Class Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA)
Common Use Management of osteoarthritis symptoms
Origin Synthetic anthraquinone derivative

Classification and Composition

Cominar is classified as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA), which sets it apart from immediate pain relievers and traditional NSAIDs. Its active component, Diacerein, is a synthetic compound that falls under the anthraquinone derivative chemical class. The drug is delivered via the oral route as a hard capsule, and its prescription-only status indicates its use requires medical supervision. Diacerein is used in the therapeutic management of osteoarthritis for its anti-inflammatory and anti-catabolic properties in joint tissue.


Targeted Cartilage Protection

Unlike immediate relief agents, Diacerein works systematically and gradually. Once absorbed, it is metabolized into the active substance, rhein, which specifically suppresses the destructive effects of the pro-inflammatory protein Interleukin-1 beta (IL-1beta). This unique mechanism aims to inhibit enzymes that degrade the cartilage matrix and reduce inflammation at its source. The medication is designed to protect the integrity of the cartilage over an extended period, leading to long-term symptomatic improvement and better joint function for patients managing persistent joint disease.

What side effects are possible with Cominar?

Cominar: Possible Side Effects and Safety Information

Note on Regulatory Documentation

Official regulatory documentation, such as the prescribing information or Summary of Product Characteristics (SmPC) from major health authorities (e.g., FDA, EMA), for a drug product specifically named "Cominar" is not available in public databases. Consequently, a comprehensive list of officially documented adverse reactions, their frequencies, and specific warnings cannot be provided.

General Safety Principles for Medicinal Products

All medications carry a risk of side effects, also known as adverse drug reactions (ADRs). These reactions are typically categorized by frequency (e.g., very common, rare) and the body system they affect (System-Organ Class, such as gastrointestinal disorders or nervous system disorders).

Key ADR Categories and Serious Adverse Reactions

Without specific data for Cominar, the following general categories apply to drugs:

Classification Area Description (General Principles)
Common Side Effects Often mild, predictable reactions related to the drug's mechanism, typically discovered during clinical trials.
Serious Adverse Reactions Any noxious and unintended response that results in hospitalization, disability, or is life-threatening. These require expedited reporting to regulatory bodies.
Population-Specific Safety Safety considerations may vary for specific groups, such as pediatric patients, the elderly, or patients with hepatic or renal impairment.
Safety Restrictions Limitations or contraindications often exist for use during pregnancy, while breastfeeding, or in patients with certain pre-existing conditions.

High-Level Safety Monitoring

Regulatory authorities conduct continuous pharmacovigilance (post-marketing surveillance) to detect new or rare safety signals once a medicine is in widespread use. Healthcare professionals are responsible for monitoring patients and reporting suspected adverse events to their national regulatory authority to ensure an ongoing, accurate understanding of the product's safety profile.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile of Cominar by its most critical manifestations: severe gastrointestinal effects and the risk of acute hepatic injury. All overdose management is based on supportive care, as no specific antidote is known.

Feature Official Regulatory Statement
Documented Manifestations The most frequent manifestation is profuse diarrhoea and abdominal pain. Severe exposure can lead to dehydration and potentially life-threatening electrolyte disturbances (Hypokalaemia) [1.2, 2.4].
Serious Outcomes Acute liver injury, hepatitis, and elevated serum hepatic enzyme levels (ALT/AST) are severe outcomes reported in post-marketing surveillance [1.1, 1.2].
Immediate Action Mandate Seek emergency medical treatment or contact the doctor if an overdose is suspected. Users must immediately contact a physician if signs of liver damage (e.g., jaundice, abdominal pain) or severe diarrhoea occur [1.2].
Population-Specific Note The drug is no longer recommended for patients aged 65 years and above due to increased risks of life-threatening complications from diarrhoea [1.1, 1.5]. It is contraindicated in patients with pre-existing liver disease [1.1, 1.2].

Management procedures must focus on symptomatic and supportive treatment, including necessary measures to manage fluid loss and electrolyte disturbances [1.2, 2.4]. Hospitalisation may be required for monitoring and investigation of severe complications [1.4].

Therapeutic Uses of Cominar

What Cominar Treats: Main Uses and Benefits

Cominar is commonly used for the long-term management of symptomatic osteoarthritis (OA). It is relevant for conditions presenting with symptomatic discomfort in joints such as the knee and hip. Its therapeutic role involves a sustained approach to symptom management, specifically for addressing symptoms in patients with hip or knee osteoarthritis.


The medication is relevant for easing symptoms that interfere with daily functioning, including chronic articular pain and joint stiffness. It is commonly used when symptoms are persistent and involve systemic or localized discomfort. Cominar is generally used for adults with moderate osteoarthritis where continuous therapeutic support is needed.

Therapeutic Support and Benefit

Cominar is used to help manage symptoms, including chronic pain, joint stiffness, and impaired functional stability. The primary therapeutic benefit is receiving sustained, long-term symptomatic support that contributes to easing the overall symptom load.

Quick Fact: Relief for Chronic Articular Pain

Eligibility and Restrictions for Use

Who Can and Cannot Use Cominar?

The use of Cominar (Diacerein) is strictly governed by regulatory guidelines, limiting its eligibility to specific patient populations and excluding others based on absolute contraindications and risk factors. The medicine is primarily intended for use in adults for the symptomatic treatment of osteoarthritis affecting the hip or knee.

Contraindicated Populations

Cominar is formally contraindicated and must not be used in the following patients:

  • Those with current or a history of liver disease.
  • Individuals with hypersensitivity to Diacerein or other anthraquinone derivatives.
  • Patients with inflammatory organic bowel disease (e.g., Crohn's disease, ulcerative colitis).

Age and Conditional Restrictions

Official regulatory documents advise specific caution for certain groups:

  • Age: Use is not recommended in patients aged 65 years and above or in children under 15 years.
  • Reproductive Status: The medicine is not recommended and must not be administered during pregnancy or lactation.
  • Treatment Cessation: Treatment must be stopped immediately if the patient develops diarrhoea, a documented restriction tied to continued use.
  • Renal Impairment: Patients with severe renal impairment (creatinine clearance below 30 ml/min) require a dose adjustment.

What should I know about interactions with other medicines?

The following information summarizes the officially documented interaction patterns of Cominar (Diacerein) with other medicinal products and substances. These constraints and requirements are mandated by government regulatory bodies and fall into the categories of pharmacodynamic risk and pharmacokinetic modification.

Interacting Substance/Product Interaction Outcome / Restriction Classification
Laxatives Co-administration is advised to be avoided due to the potential for acute diarrhoea and severe gastrointestinal disturbance. Avoid Combination
Diuretics (Loop and Thiazides) Caution required due to the additive risk of hypokalemia and dehydration arising from potential diarrhoea. Use with Caution
Cardiac Glycosides (e.g., Digoxin) Caution is mandated, as potential hypokalemia may increase the risk of cardiac arrhythmias. Use with Caution
Antacids (Aluminum, Calcium, Magnesium salts) Leads to reduced digestive absorption of Diacerein. Must be administered with a mandatory separation of more than two hours. Timing Separation Required

Additional Interaction Constraints

The regulatory profile includes constraints regarding additive risk. Caution is required when Cominar is used concurrently with other medicinal products associated with hepatic injury due to the potential for an additive risk of hepatotoxicity. Patients are officially advised to limit alcohol intake during treatment due to the same risk. Furthermore, taking the capsule with a main meal is documented to increase the bioavailability of the active metabolite.

Mechanism of Action

Cytokine Signal Inhibition and Pathway Antagonism

The mechanism of action is characterized by a core anti-catabolic effect on joint tissue, focusing on the modulation of underlying biochemical pathways. The active molecule, Rhein, targets the drivers of cartilage degradation by inhibiting the synthesis and activation of the pro-inflammatory cytokine, Interleukin-1β (IL-1β). This is achieved by reducing the activity of IL-1 Converting Enzyme (ICE) and downregulating IL-1 receptors on chondrocytes. This targeted action functionally antagonizes the cytokine system, dampening IL-1beta signal transduction.

Cartilage Matrix Stabilization and Catabolic Suppression

By reducing the IL-1beta signal, the drug suppresses the downstream production of catabolic enzymes like Matrix Metalloproteinases (MMPs) and ADAMTS (Aggrecanases), which degrade the cartilage matrix. Furthermore, Rhein promotes the anabolic (building) activity of the chondrocytes, encouraging the synthesis of essential structural components. This dual modulation of catabolism and anabolism results in the stabilization of the cartilage matrix balance.

Mechanistic Profile

Because its action relies on modulation of the IL-1 signaling axis rather than inhibition of the COX pathway, the resulting physiological effects—the modulation of tissue balance—are gradual and sustained, emerging over a period determined by the kinetics of pathway downregulation.

Dosage and Administration Information

How Cominar is Used

Cominar (Diacerein) is administered via the oral route as a hard capsule, following a defined two-stage regimen. Treatment is generally initiated and overseen by a specialist experienced in managing symptomatic osteoarthritis.


Standard Dosing Protocol

The protocol begins with an initial, lower dose to establish tolerability before advancing to the long-term maintenance dose. The medication is intended for continuous, long-term use.

Phase Daily Dose Frequency Contextual Timing
Initial Phase 50 mg Once daily For the first 2 to 4 weeks
Maintenance Phase 100 mg Twice daily (50 mg per dose) Following the initial phase

Key Administration Rules

The hard capsules must be swallowed whole and intact with a glass of water; they are not intended to be opened, crushed, or chewed. Each dose must be taken with food, with the twice-daily regimen typically aligning with breakfast and the evening meal, a practice necessary to ensure proper absorption.

Population-Specific Use Restrictions

Specific limitations apply to certain patient groups. The daily dose is halved to 50 mg once daily for patients diagnosed with severe renal impairment (creatinine clearance below 30 ml/min). Furthermore, use is generally not recommended for patients under 15 years of age or for those over 65 years. The protocol also involves avoiding the concomitant intake of laxative medications.

Recent Clinical Evidence

Research Evidence Overview

This section summarizes the official research evidence for Cominar (Diacerein), focusing on the types of clinical trials, the patient populations studied, and the scientific outcomes that regulators and researchers considered. It describes what the evidence has explored so far and what the research highlights as areas of uncertainty.


Evidence for Symptom Management in Osteoarthritis of the Knee and Hip

The primary research for Cominar was evaluated in studies focusing on adults managing symptomatic osteoarthritis of the knee and hip. This research involves Randomized Controlled Trials (RCTs) and Systematic Reviews that explore how symptoms change over time during treatment.

Research examined how patient-reported experiences related to physical discomfort and daily functioning evolved in the observed populations. These studies often tracked short-term changes over periods ranging from a few weeks up to six months. Findings describe patterns observed in the studies related to changes in symptoms. The evidence indicates patterns where symptomatic changes, when present, were often described in regulatory assessments as modest in magnitude and delayed in onset.


Research on Potential Structural Effects in Joint Disease

Cominar was studied for its potential impact on the physical progression of osteoarthritis. This was researched in long-term RCTs, with some studies monitoring patients for up to three years. These studies examined the possibility that the medication could affect the condition marked by functional limitations over time.

Long-term RCTs involved tracking the rate of Joint Space Narrowing (JSN), a metric used by researchers to assess cartilage structure change. The evidence remains limited, and findings were mixed; data show patterns related to JSN in some joints, such as the hip, but these findings were uncertain or conflicting when applied to the knee.


What the Research Still Shows as Uncertain

The overall research landscape has several acknowledged limitations and areas where certainty remains low:

  • Inconsistency and Quality: Evidence quality varies across studies, and results were inconsistent for symptomatic outcomes. This inconsistency makes it difficult to draw broad, consistent conclusions about the research patterns observed compared to placebo.
  • Generalizability: Follow-up durations were limited in many initial symptomatic trials. Therefore, there is limited information for long-term outcomes, and the results apply primarily to the specific populations studied, meaning research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials - Database of Abstracts of Reviews of Effects (DARE) - NCBI
  2. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis

Frequently Asked Questions (FAQ)

Common questions about Cominar (FAQ)


Q: How long does Cominar typically take to start working?

A: Cominar is classified as a symptomatic slow-acting drug, meaning its therapeutic effects are not immediate. Official studies indicate that symptomatic improvement may begin after a few weeks, and full symptomatic changes are typically noted in studies after 6 to 8 weeks of continuous use.


Q: Are there any serious side effects associated with Cominar that I should know about?

A: Official product information describes the risk of severe diarrhoea, which can potentially lead to dehydration and imbalances in body salts. There have also been reports of acute hepatic injury, including severe liver damage, so official guidelines require careful monitoring of the liver.


Q: Can I use alcohol while I am using Cominar?

A: Official guidelines recommend limiting alcohol intake during treatment. This caution is due to a potential additive risk of toxicity to the liver, as the medication already carries a safety warning related to hepatic risk.


Q: Are there any specific medications that interact badly with Cominar?

A: Yes, official documentation advises caution regarding several types of medications. For example, co-administration with laxatives should be avoided, and timing separation is required for antacids. Caution is also noted for certain diuretics and cardiac glycosides due to potential risks like electrolyte imbalance.


Q: Does taking Cominar with food change how it works?

A: Official documents state that the administration protocol requires taking Cominar with a main meal. This practice helps ensure optimal absorption and manage gastrointestinal tolerability.


Q: Can I take Cominar if I have a history of liver problems?

A: Official regulatory guidelines state that this medicine is formally contraindicated in patients with either current liver disease or a confirmed history of liver disease. It must not be used in these populations.


Q: How long does the effect of one dose of Cominar last?

A: The active substance leaves the bloodstream over a period that is documented to be around 5 to 7 hours. However, since the medicine works gradually by modifying disease pathways, its overall beneficial effect on joint tissue is sustained and is not solely dependent on the concentration of a single dose.


Q: Does Cominar have a generic version available?

A: Cominar contains the active ingredient Diacerein. According to official drug information databases, the substance diacerein is available under various generic forms and different brand names internationally.


Q: Is Cominar a type of antibiotic?

A: No, Cominar is not an antibiotic. It is officially classified as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA). Its active component is a synthetic chemical and is not used to treat bacterial infections.


Q: Is Cominar an anti-inflammatory medication?

A: Yes, the mechanism of action is described as having both anti-catabolic and anti-inflammatory properties. This is achieved through its anti-catabolic properties, which include reducing the effect of inflammatory proteins in the joints.


Q: What kind of side effects are common with Cominar?

A: The most common side effects documented in clinical data are gastrointestinal, specifically loose stools and diarrhoea. Other common reports include gastrointestinal issues like abdominal pain, nausea, and a change in urine color to a dark yellow or brownish shade.


Q: Do side effects from Cominar usually go away after a few days?

A: The most frequently reported gastrointestinal issues, such as diarrhoea, are often reported shortly after beginning treatment and, in many cases, lessen over the initial 2 to 4 weeks of continuous use.


Q: Can Cominar cause stomach upset?

A: Official product information describes common side effects that include gastrointestinal upset, specifically abdominal pain and nausea. Very common side effects include loose stools and diarrhoea.


Q: Is it normal to feel tired after starting Cominar?

A: Official documentation lists fatigue as a general side effect that may be experienced by some patients while taking the medicine. These types of effects are typically described as mild.


Q: Is it normal if Cominar makes me feel a bit dizzy?

A: Dizziness is included in the official documentation among the general side effects that some patients have reported while taking this medicine.


Q: Are there different strengths of Cominar available?

A: Cominar is typically supplied as a 50 mg hard capsule. The standard dosing protocol uses this 50 mg strength to achieve the necessary treatment levels.


Q: Is Cominar used to treat chronic conditions?

A: Yes. Cominar is officially indicated as a prescription medication designed for the long-term management of symptoms associated with osteoarthritis, which is considered a chronic joint condition.


Q: Does Cominar contain aspirin or Tylenol (acetaminophen)?

A: No. The active ingredient in Cominar is Diacerein, which is chemically distinct from both aspirin and Tylenol (acetaminophen). These common pain-relieving substances are not listed as components of Cominar.


Q: Are there any known issues with taking Cominar and driving?

A: Official regulatory documents do not cite specific studies on driving performance. However, because side effects such as dizziness and fatigue have been reported, caution is generally advised if you experience any effects that might impair your ability to drive or operate machinery.


Q: Can pregnant women use Cominar?

A: No. Official regulatory documents state that Cominar is not recommended for use during pregnancy or lactation.


Q: Is it common for doctors to start patients on a low dose of Cominar?

A: Yes. The official standard protocol for use begins with a lower dose for the first 2 to 4 weeks. This practice is implemented to help patients adjust to the medication and to improve gastrointestinal tolerability.


Q: Why is it important to check drug interactions for Cominar?

A: It is important because official documentation indicates that combining Cominar with certain other drugs can lead to increased risks. These risks include the potential for dehydration, electrolyte imbalances, and the accumulation of liver toxicity.


Q: What are the common signs of an allergic reaction to Cominar?

A: The medicine is contraindicated for hypersensitivity to its components. Common signs of allergy described in drug information include skin reactions such as itching and a rash, and in rare cases, more severe skin reactions have been reported.

How should Cominar be stored and disposed of?

How to Store and Dispose of Cominar

Storage of Cominar (Diacerein hard capsules) must strictly follow official regulatory requirements to maintain product stability and safety.

Official Storage Requirements

Condition Requirement
Temperature Store below 30 C (Controlled Room Temperature). Do not refrigerate or freeze.
Protection Protect from light and moisture. Store in a dry place.
Packaging Keep in the original container or blister pack with the receptacle tightly sealed.
Child Safety Keep out of reach of children.

Disposal

Dispose of unused medicine according to local protocols. Ensure the discarded product is not consumed by pets, children, or other people.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cominar found in:

A-Z Index: